Summary The immunomodulatory effect of prophylactic intravesical instillations of interferon alpha 2b (IFN-a-2b) on interferon gamma (IFN-y) and interleukin 4 (IL-4) production by peripheral blood mononuclear cells (PBMCs) from patients with superficial transitional cell carcinoma (STCC) of the bladder has been analysed. There were no significant differences in the production of IFN-y and IL-4 by PBMCs from untreated patients and healthy control subjects after 24 h of phytohaemagglutinin (PHA) stimulation. However, between 3 and 6 months after finishing the prophylactic intracavitary treatment with IFN-a-2b, PHA-stimulated PBMCs from patients with STCC of the bladder showed a significantly enhanced production of IFN-y and a significantly decreased production of IL-4. Both IFN-y and IL-4 returned to pretreatment levels 1 year after ending the treatment. In conclusion, prophylactic intravesical instillations of IFN-a-2b in patients with STCC of the bladder have an immunoregulatory effect on the production of IFN-y and IL-4 by PBMCs.
Summary The immunomodulatory effect of prophylactic intravesical instillations of interferon alpha 2b (IFN-a-2b) on interferon gamma (IFN-y) and interleukin 4 (IL-4) production by peripheral blood mononuclear cells (PBMCs) from patients with superficial transitional cell carcinoma (STCC) of the bladder has been analysed. There were no significant differences in the production of IFN-y and IL-4 by PBMCs from untreated patients and healthy control subjects after 24 h of phytohaemagglutinin (PHA) stimulation. However, between 3 and 6 months after finishing the prophylactic intracavitary treatment with IFN-a-2b, PHA-stimulated PBMCs from patients with STCC of the bladder showed a significantly enhanced production of IFN-y and a significantly decreased production of IL-4. Both IFN-y and IL-4 returned to pretreatment levels 1 year after ending the treatment. In conclusion, prophylactic intravesical instillations of IFN-a-2b in patients with STCC of the bladder have an immunoregulatory effect on the production of by PBMCs. Keywords: superficial transitional cell carcinoma; interferon a; interferon y, interleukin 4 Superficial transitional cell carcinoma (STCC) of the bladder is most often characterized by its high rate of recurrence following the initial endoscopic surgical resection, despite the absence of any identifiable remaining tumour (Torti and Lum, 1987) . The heterogeneous natural history of STCC of the bladder (Lynch et al, 1991) after its endoscopic surgical resection provides a powerful rationale for the use of adjuvant intravesical therapy, in order to prevent the recurrence and progression of the disease. At present, the prophylactic use of intravesical chemotherapy in these patients continues to be of limited effectiveness, as it has failed to reduce significantly the rate of disease progression and long-term tumour recurrence (Lamm et al, 1992) . Prophylactic immunotherapy of STCC, as exemplified by intravesical instillations with Bacillus Calmette-Guerin (BCG), has achieved positive results with a significant improvement in survival, presumably because of its ability to induce an effective immune response to tumours (Prescott et al, 1992; Kaempfer et al, 1996) . However (Jurincic et al, 1988; Glashan, 1990) . The potential use of interferon alpha (IFN-a) as adjuvant prophylactic treatment of STCC of the bladder has also been investigated (Glashan, 1990 (Einat et al, 1985; Molto et al, 1994; Singh et al, 1995) . It has been shown that prophylactic intravesical instillations of IFN-a in patients with STCC are associated with in vivo immunomodulatory effects. Regulatory effects of intravesical instillations of IFN-a have been observed in PBMCs from patients with STCC of the bladder. These effects include an enhancement of NK-cell activity and a proliferative response to T-lymphocyte mitogens (Molt6 et al, 1994 (Molt6 et al, , 1995 .
Cytokines play an important role in the regulation of the function of the different immune cell populations. In this sense, several cytokines produced by T (Seder & Paul, 1994) . These cytokines show different regulatory effects on the activation of T lymphocytes and NK cells.
In this paper we investigate the effects of prophylactic intracavitary instillations of IFN-ax-2b on the production of IFN-y and IL-4 by phytohaemagglutinin (PHA)-stimulated PBMCs in patients with STCC of the bladder.
PATIENTS AND METHODS Patients and treatments
Seventeen patients with histological proven transitional cell carcinoma of the bladder were analysed. The extent of tumour invasion was classified according to the tumour, node and metastasis no statistically significant differences in PBMC production of IFN-y between the patients with STCC of the bladder and the healthy control subjects (P > 0.05) (Figure lA) . The effect of IFN-a-2b in the culture medium on the production of IFN-y by PHA-stimulated PBMCs from patients and healthy control subjects was also studied. As shown in Figure 2A , the production of IFN-y by PHA-stimulated PBMCs from STCC patients, studied before treatment and 3-6 months after finishing the 3-month treatment with intracavitary IFN-a-2b instillations, and from healthy control subjects, was significantly enhanced in the presence of IFN-a-2b in the culture medium (P < 0.05).
The effects of prophylactic IFN-a-2b intravesical instillations on the production of IFN-y by PHA-stimulated PBMCs in patients were analysed several times during the first year of follow-up. As shown in Figure 3 , there was no increase in the production of IFNy by PHA-stimulated PBMCs from patients during the second month of treatment (P > 0.05). The increase in IFN-y production by PHA-stimulated PBMCs from patients analysed between 3 and 6 months after finishing the treatment, with respect to that found before initiating the treatment and during the 3 months of intracavitary IFN-a-2b instillations, was significant (P < 0.05). There were no significant differences in IFN-y production by PHA-stimulated PBMCs from patients before the treatment and 1 year after finishing the intracavitary instillations with IFN-a-2b (P > 0.05). IL-4 production was studied at the same time and under the same conditions as IFN-y production. There were no statistically significant differences in the production of IL-4 by PBMCs between untreated STCC patients and healthy control subjects (P > 0.05) ( Figure IB) .
The effect of IFN-a-2b on the production of IL-4 by PHA-stimulated PBMCs from patients with STCC of the bladder, before treatment and 3-6 months after finishing the intracavitary IFN-a-2b instillations and from healthy control subjects was examined. Figure  2B , shows that in both healthy control subjects and patients the exogenous addition of IFN-a-2b to the culture medium of PHAstimulated PBMCs did not significantly modify the production of IL-4 with respect to that achieved in its absence (P > 0.05).
The effects of the prophylactic intravesical instillation of IFNa-2b on the production of IL-4 by PHA-stimulated PBMCs from the patients during a year's follow-up was also studied. As shown in Figure 3 , there were no significant differences in IL-4 production by PHA-stimulated PBMCs from patients measured during the second month of treatment with intracavitary instillations of IFN-a-2b, and that found before treatment (P > 0.05). However, there was a significant decrease in IL-4 production by PHA-stimulated PBMCs from patients when analysed between 3 and 6 months after finishing the treatment, with respect to that found before initiating the treatment (P < 0.05). There were no significant differences between IL-4 production by PHAstimulated PBMCs from patients before treatment and that after 1 year of finishing the intracavitary instillations with IFN-a-2b (P > 0.05) (Figure 3 ).
IFN-y and IL-4 production by PHA-activated PBMCs was analysed in six healthy control subjects at the beginning and at the end of a 6-month period. No significant differences were found in the cytokine production between these samples (P > 0.05) (data not shown).
As shown in Table 2 , there were no significant differences in the percentages of cells that express the antigens CD3, CD16/56, CD19, CD4 and CD8 in PBMCs from untreated patients with STCC of the bladder and healthy control subjects. However, 3 and 6 months after finishing the 3-months intracavitary instillations with IFN-a-2b, the percentage of CD4+ lymphocytes and the CD4+/CD8+ ratio in PBMCs from STCC patients were significantly decreased compared with those found in healthy control subjects (P < 0.05), but there were no significant differences with respect to the values found in these patients before their intracavitary treatment (P > 0.05).
DISCUSSION
The cytokines IFN-y and IL-4 play a pivotal role in the regulation of the immune response induced by antigenic stimulation. IFN-,y is mainly produced by T lymphocytes and NK cells. It is known that IFN-y regulates the activation of putative anti-tumour effector cells, including macrophages, NK cells and cytotoxic T lymphocytes (Kasahara et al, 1983; Murakata et al, 1985) . IFN-y production by PBMCs is frequently impaired in patients with advanced neoplasms (Ikemoto et al, 1990) . is mainly produced by T lymphocytes (Hayakawa et al, 1991) . IL-4 is involved in the modulation of activation and proliferation of cytotoxic T lymphocytes, and there are controversial reports about its effects on NK cells (Hayakawa et al, 1991; Spits et al, 1988; Higuchi et al, 1989) . There is increasing evidence that different subsets of T lymphocytes have different patterns of cytokine secretion, as defined according to the preferential secretion of IFN-,y or IL-4, called Th1 and Th2 respectively. It appears that both T-lymphocyte subsets negatively cross-regulate each other (Heinzel et al, 1989) .
Our results show that PBMCs from untreated patients with STCC of the bladder have a normal production of IFN-y and IL-4.
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Intracavitary prophylactic treatment with IFN-a-2b in these patients is associated with a significant modification of the pattern of PBMC secretion of these two cytokines. The increased IFN-y production parallels a decreased IL-4 production by PBMCs from these patients. This effect is mainly observed 3-6 months after finishing the intracavitary treatment with IFN-a-2b and has virtually disappeared after 12 months of follow-up. These modifications in the pattern of IFN-y and IL-4 secretion by PBMCs found in patients with STCC of the bladder prophylactically treated with intracavitary IFN-a-2b instillations suggest that the induction of a bias towards the preferential use and/or activation of the Tlymphocyte subset that produces IFN-y in these patients. The Th, subset appears to be mainly implicated in the regulation of immune responses involving cytotoxic T lymphocytes and NK cells. It seems that the modification in the pattern of cytokine secretion by PBMCs from STCC patients treated with intracavitary IFN-a-2b, might be involved in the described activation of NK cells and T lymphocytes found in the peripheral blood of these patients (Molt6 et al, 1994 (Molt6 et al, , 1995 .
Our findings clearly show that prophylactic intracavitary treatment with IFN-a-2b in patients with STCC of the bladder not only has a local effect on the bladder wall, but also has a systemic immunomodulatory effect on the T-lymphocyte compartment, with a marked functional consequence on the pattern of lymphokine secretion. The mechanism by which a locally administered cytokine can induce an extended systemic effect is as yet unknown. Perhaps the intravesical instillations of IFN-a induce a local immune response in the bladder wall that has a delayed systemic consequence. The systemic effects of intravesical instillations with IFN-a might be explained by the recirculation of locally activated T lymphocytes and/or as a consequence of the generalized functional interactions found in the immune system. According to the known biological effects of LFN-a, the mechanisms of action of the intravesical instillations of IFN-a as a prophylactic anti-tumoral treatment might be multiple (Einat et al, 1985; Singh et al, 1995) . The potential 'clinical significance of these findings has to be studied. The analysis of the immunoregulatory effects of IFN-a may be a useful tool in the optimization of this therapeutical modality in the prophylaxis of the recurrences of STCC of the bladder. Our data clearly show that the prophylactic intracavitary treatment of patients with STCC of the bladder with IFN-a-2b has a transient systemic immunomodulatory effect. It might be possible to suggest that the maintenance of the immune system activation could improve the clinical results obtained with prophylactic instillations of IFN-a in patients with STCC of the bladder. However, analysis of the potential clinical significance of the immunomodulatory effects of the prophylactic intracavitary instillations of IFN-a-2b in patients with STCC of the bladder requires further studies.
